{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T22:23:33Z","timestamp":1772922213099,"version":"3.50.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"10","content-domain":{"domain":["ecco-jccjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Crohn's and Colitis"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.crohns.2013.03.004","type":"journal-article","created":{"date-parts":[[2013,4,16]],"date-time":"2013-04-16T16:47:08Z","timestamp":1366130828000},"page":"e486-e492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Tuberculosis in anti-TNF-\u03b1 treated patients remains a problem in countries with an intermediate incidence: Analysis of 25 patients matched with a control population"],"prefix":"10.1093","volume":"7","author":[{"given":"C\u00e2ndida","family":"Abreu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Magro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o","family":"Santos-Antunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur","family":"Pil\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Rodrigues-Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Bernardes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Magina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filipe","family":"Vilas-Boas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme","family":"Macedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ant\u00f3nio","family":"Sarmento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"10.1016\/j.crohns.2013.03.004_bb0005","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2013.03.004_bb0010","series-title":"Manufacturers of TNF blocker drugs must highlight risk of fungal infection","author":"US Food and Drug administration","year":"2008"},{"key":"10.1016\/j.crohns.2013.03.004_bb0015","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.crohns.2013.03.004_bb0020","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2013.03.004_bb0025","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s10620-006-9250-x","article-title":"Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases","volume":"52","author":"Kaur","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.crohns.2013.03.004_bb0030","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1002\/art.11151","article-title":"Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression","volume":"48","author":"Netea","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2013.03.004_bb0035","article-title":"Listeria infection in patients on anti-TNF treatment: report of two cases and review of the literature","author":"Abreu","year":"2012","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.crohns.2013.03.004_bb0040","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1002\/art.11301","article-title":"Infections and anti tumor necrosis factor alpha therapy","volume":"48","author":"Ellerin","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2013.03.004_bb0045","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2013.03.004_bb0050","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.crohns.2013.03.004_bb0055","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.berh.2011.06.001","article-title":"Tuberculosis and other infections in the anti-tumour necrosis factor-alpha (anti-TNF-\u03b1) era","volume":"25","author":"Nacci","year":"2011","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.crohns.2013.03.004_bb0060","series-title":"Relatorio para o dia Mundial da Tuberculose","author":"Fonseca Antunes","year":"2011"},{"key":"10.1016\/j.crohns.2013.03.004_bb0065","first-page":"237","article-title":"Recomenda\u00e7\u00f5es para diagn\u00f3stico e tratamento da tuberculose latente e activa nas doen\u00e7as inflamat\u00f3rias articulares candidatas a tratamento com f\u00e1rmacos inibidores do factor de necrose alfa","volume":"31","author":"Fonseca","year":"2006","journal-title":"Acta Reumatol Port"},{"key":"10.1016\/j.crohns.2013.03.004_bb0070","series-title":"Unite de la Tuberculose et des mycobact\u00e9ries","article-title":"M\u00e9thodes de laboratoire pour mycobact\u00e9riologie clinique","author":"David","year":"1989"},{"key":"10.1016\/j.crohns.2013.03.004_bb0075","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk","volume":"48","author":"Gomez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.crohns.2013.03.004_bb0080","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2174\/138945010790310009","article-title":"How to manage the infectious risk under anti-TNF in inflammatory bowel disease","volume":"11","author":"Culver","year":"2010","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.crohns.2013.03.004_bb0085","first-page":"1436","article-title":"Increased risk of tuberculosis in patients with rheumatoid arthritis","volume":"30","author":"Carmona","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.crohns.2013.03.004_bb0090","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1136\/ard.2005.047274","article-title":"Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan","volume":"65","author":"Yamada","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.crohns.2013.03.004_bb0095","first-page":"1127","article-title":"Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis","volume":"10","author":"Sichletidis","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.crohns.2013.03.004_bb0100","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","article-title":"Anti-tumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management","volume":"3","author":"Gardam","year":"2003","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.crohns.2013.03.004_bb0105","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/art.34382","article-title":"Interferon-gamma release assay versus tuberculin skin test across RA, PsA, and AS patients prior to treatment with golimumab, a human anti-TNF antibody","volume":"64","author":"Elizabeth","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2013.03.004_bb0110","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"49","author":"Centers for Disease Control and Prevention","year":"2000","journal-title":"MMWR"},{"issue":"2","key":"10.1016\/j.crohns.2013.03.004_bb0115","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0891-5520(05)70154-9","article-title":"Infections associated with steroids use","volume":"15","author":"Klein","year":"2001","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.crohns.2013.03.004_bb0120","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1086\/587989","volume":"46","author":"Kevin","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.crohns.2013.03.004_bb0125","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1086\/427941","article-title":"Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis","volume":"40","author":"Garcia","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.crohns.2013.03.004_bb0130","first-page":"1057","article-title":"Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab","volume":"9","author":"Belknap","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.crohns.2013.03.004_bb0135","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00002030-200401230-00015","article-title":"A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis","volume":"18","author":"Wallis","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.crohns.2013.03.004_bb0140","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1086\/522993","article-title":"A patient with de novo tuberculosis during anti-tumor necrosis factor-\u03b1 therapy illustrating diagnostic pitfalls and paradoxical response to treatment","volume":"45","author":"Arend","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"15","key":"10.1016\/j.crohns.2013.03.004_bb0145","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994613001086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994613001086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/7\/10\/e486\/1080772\/7-10-e486.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T13:02:46Z","timestamp":1562936566000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-lookup\/doi\/10.1016\/j.crohns.2013.03.004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S1873994613001086"],"URL":"https:\/\/doi.org\/10.1016\/j.crohns.2013.03.004","relation":{},"ISSN":["1873-9946"],"issn-type":[{"value":"1873-9946","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tuberculosis in anti-TNF-\u03b1 treated patients remains a problem in countries with an intermediate incidence: Analysis of 25 patients matched with a control population","name":"articletitle","label":"Article Title"},{"value":"Journal of Crohn's and Colitis","name":"journaltitle","label":"Journal Title"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.crohns.2013.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}